Risk markers to prevent diabetic nephropathy.
Phenotyping diabetic nephropathy in type 1 diabetes with an ‘omics’ and marker approach in a new cohort, searching for novel mechanisms which underlie the renal function decline as well as markers identifying subjects where these pathways are activated.
The phenotyping consist of:
1. The glycocalyx thickness as a marker of microvascular function assessed by a handheld video capillary microscope under the tongue in type 1 diabetes with normo-, micro- and macro albuminuria
2. Characterisation of the gut microbiota by microbial 16S and deep DNA sequencing from fecal samples
3. Biomarkers based on the gut microbiota and plasma metabolomics
4. Flow Cytometry Analysis (analysed by a dedicated Post Doc at Novo Nordisk in Måløv) to distinguish circulating cells in blood and urine related to renal complications
Through this phenotyping we aim to enhance the understanding of the pathophysiology of diabetic nephropathy and will promote sub classification of patients.
PeRsOnalising Treatment Of diabetic Nephropathy: From albuminuria to multidimensional characterisation of diabetic nephropathy.
A cross-sectional study of 160 patients of type 1 diabetes with different level of diabetic kidney disease recruited from Steno Diabetes Center and 50 healthy non-diabetic controls.
Aim: Phenotyping with assessment of glycocalyx thickness characterisation of the gut microbiota, metabolomics and other gut related biomarkers.
Collaborators: Professor Oluf Pedersen and Torben Hansen, The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of metabolic Genetics, University of Copenhagen, NNF centre of metabolic research , Department of system medicine, SDCC, PostDoc Dana Kyluik-Price, Novo Nordisk, Måløv,
Professor Per-Henrik Groop, Folkhälsan Research Center/FinnDiane Biomedicum, Helsinki
Systems Medicine Analyses of gut related metabolomics in type 1 diabetes:
Early prediction of cardiovascular and renal complications in patients with type 1 diabetes using Trimethylamine-N-Oxide (TMAO) as a risk marker.
Collaborations: Professor Oluf Pedersen, NNF centre of metabolic research,
Department of system medicine, SDCC and Professor Stanley Hazen, Cleveland Clinic, Ohio, US